Nur Hezrin Shahrin - Concepedia

Author

Nur Hezrin Shahrin

Centre for Cancer Biology ORCID

Also Known As

Hezrin Shahrin, N. Shahrin, NUR Hezrin Shahrin, Nur H. Shahrin, Nur Hezrin Shahrin, NurHezrin Shahrin

Publications

504

Citations

H-Index

Concepts

All Affiliations

Centre for Cancer Biology University of South Australia South Australia Pathology The University of Adelaide South Australian Health and Medical Research Institute

About

Nur Hezrin Shahrin is an author at Centre for Cancer Biology specializing in cell biology, medicine, and molecular diagnostics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	67
2	Cell Biology	2	2	67
3	Health Sciences	1	1	24
4	Immunology	1	1	43
5	Pathology	1	1	24

Nur Hezrin Shahrin

Publications

459

Citations

H-Index

Page 1

	Year	Citations
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease Susan Branford, Paul Wang, David T Yeung, Blood	2018	203
Conditional knockout mice demonstrate function of Klf5 as a myeloid transcription factor Nur Hezrin Shahrin, Sonya M. Diakiw, Lindsay A. Dent, Blood	2016	66
GATA2 deficiency syndrome: A decade of discovery Claire C. Homan, Parvathy Venugopal, Peer Arts, Human Mutation	2021	66
Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia Daniel Thomson, Nur Hezrin Shahrin, Paul Wang, Leukemia Hematological MalignancyChromatinChronic Myeloid LeukemiaMixed-phenotype Acute LeukemiaGenetics	2020	43
Impaired haematopoietic stem cell differentiation and enhanced skewing towards myeloid progenitors in aged caspase-2-deficient mice Swati Dawar, Nur Hezrin Shahrin, Nikolina Sladojevic, Cell Death and Disease	2016	34
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention Naranie Shanmuganathan, Carol Wadham, Nur Hezrin Shahrin, Haematologica Mixed-phenotype Acute LeukemiaPathologyTumor BiologyMyeloid NeoplasiaHematological Malignancy	2023	24
Beyond BCR::ABL1—The Role of Genomic Analyses in the Management of CML Susan Branford, Adelina Fernandes, Nur Hezrin Shahrin, Journal of the National Comprehensive Cancer Network	2024	13
Strong Association between Cancer Gene Variants at Diagnosis, Especially <i>ASXL1</i>, and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors Naranie Shanmuganathan, Carol Wadham, David T Yeung, Blood	2024	10

Page 1